GenMark Diagnostics Inc. (NASDAQ:GNMK) has a beta of 3.02. The stock’s Relative Strength Index (RSI) is 66.37, with weekly volatility at 0.26% and ATR at 0.48. The GNMK stock’s 52-week price range has touched low of $7.00 and a $24.25 high. Its shares traded higher over the last trading session, gaining 0.08% on 04/16/21. The shares fell to a low of $23.99 before closing at $24.01. Intraday shares traded counted 1.24 million, which was 58.7% higher than its 30-day average trading volume of 3.01M. GNMK’s previous close was $23.99 while the outstanding shares total 71.81M.
Investors have identified the Medical Devices company GenMark Diagnostics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.77 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
GenMark Diagnostics Inc. (GNMK) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 172.96 million total, with 44.13 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 0.14 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on GNMK sounds very interesting.
Is the stock of GNMK attractive?
In related news, SVP, Engineering and Tech Dev, Jensen Tyler sold 500 shares of the company’s stock in a transaction that recorded on Mar 18. The sale was performed at an average price of 23.88, for a total value of 11,940. As the sale deal closes, the VP, Assay Development, Shaw Christine now sold 274 shares of the company’s stock, valued at 5,085. Also, SVP, Engineering and Tech Dev, Jensen Tyler sold 500 shares of the company’s stock in a deal that was recorded on Mar 04. The shares were price at an average price of 18.86 per share, with a total market value of 9,430. Following this completion of acquisition, the VP, Qual, Reg, & Clin Affairs, Maderazo Alan Baer now holds 2,127 shares of the company’s stock, valued at 40,817. In the last 6 months, insiders have changed their ownership in shares of company stock by 4.40%.
0 out of 6 analysts covering the stock have rated it a Buy, while 6 have maintained a Hold recommendation on GenMark Diagnostics Inc.. 0 analysts has assigned a Sell rating on the GNMK stock. The 12-month mean consensus price target for the company’s shares has been set at $23.03.